Discovery of New Antimalarial Drug Candidates
Walter and Eliza Hall Institute of Medical Research
1g Royal Parade
See more events from
In recent years there has been an increased focus on the discovery and development of new antimalarial combination therapies that improve patient compliance and reduce treatment costs compared to the current three-day dosing regimen. While the benefits of this goal are clear, it places heavy demands on drug discovery scientists to deliver not only potent molecules that act on multiple stages of the parasite life-cycle with no cross-resistance to existing drugs, but also molecules that have an extended duration of pharmacological exposure making them suitable for single dose administration. This ambitious goal presents significant challenges to find the right balance of potency, selectivity, safety, developability and pharmacokinetic properties to deliver a long half-life and extended duration of exposure. In this presentation, some of these challenges will be discussed.